Labeling Type
CELLULAR THERAPY
Status
Approved
Full Title
These highlights do not include all the information needed to use TECARTUS safely and effectively. See full prescribing information for TECARTUS. TECARTUS (brexucabtagene autoleucel) suspension for intravenous infusion Initial U.S. Approval: 2020
United States
Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.
